| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05845359 Details | 2023-10-18 Interventional | 4 | 0 | Methadone Pain, Postopera… Bariatric Surge… | IRB approval never received - | |||
| NCT04979442 Details | 2023-10-18 Interventional | 3 | 175 | Trabectedin Liposarcoma Dedifferentiate… | Sponsor Decision - | |||
| NCT04591808 Details | 2023-10-18 Interventional | 3 | 146 | Atorvastatin Perindopril Dyslipidemias Hypertension | for strategic reasons - | |||
| NCT05867030 Details | 2023-10-17 Interventional | 1 | 0 | Lenalidomide Rituximab Lymphoma Lymphoma, Folli… Follicular Lymp… | Development strategy adjustment - | |||
| NCT04404140 2019-004591-19 Details | 2023-10-17 Interventional | 1 | 6 | Atezolizumab Docetaxel Ipatasertib Prostatic Neopl… Prostatic Neopl… Castration-Resi… | Despite many risk-minimization strategies, the combination of ipatasertib, atezolizumab and
docetaxel was challenging due to multiple study treatment modifications required to manage
toxicity, making further enrollment inappropriate. - | |||
| NCT04108481 Details | 2023-10-17 Interventional | 1/2 | - | Antibodies, Mon… Durvalumab Methamphetamine Colonic Neoplas… Colorectal Neop… Liver Neoplasms Neoplasm Metast… Neoplasms, Seco… Rectal Neoplasm… Colo-rectal Can… Colon Cancer Colorectal Aden… Colorectal Canc… Colorectal Carc… Liver Metastase… Liver Metastasi… Metastatic Colo… Rectal Cancer | Working on revisions - | |||
| NCT03769181 2018-002442-37 Details | 2023-10-17 Interventional | 1/2 | 58 | Cemiplimab Lymphoma | Study was stopped after interim analysis for all 4 cohorts with results either not fulfilling
the pre-planned interim analysis criteria or fulfilling the criteria but as per sponsor
decision. It was not due to any safety concern The efficacy results observed in Cohorts B and C did not fulfill the pre-planned interim analysis criteria allowing the study to move to Phase 2 Stage 2 in these cohorts. The efficacy results observed in Cohort A1 and A2 fulfilled the pre-planned interim analysis criteria in Stage 1 to move to Phase 2 Stage 2 in these cohorts. However, the study was stopped for all the cohorts as per Sponsor's decision. | |||
| NCT04984317 Details | 2023-10-16 Interventional | 1 | - | Botulinum Toxin… abobotulinumtox… Enuresis Urinary Inconti… Urinary Inconti… Stress Urinary … | Principal Investigator changing locations. - | |||
| NCT04790487 Details | 2023-10-16 Interventional | 2/3 | 0 | Chlorpheniramin… Rhinitis Rhinitis, Aller… Allergic Rhinit… Nasal Congestio… | Study Period Ended/Not Completed - | |||
| NCT04260607 Details | 2023-10-16 Interventional | 3 | [43 Refs] | 2 | Ketamine Emergencies Suicide Depression Seve… Suicide Threat | As a busy MTF we were unable to retain a health care provider with the appropriate expertise to
buy-in to this study once the initiating PI left military service. - | ||
| NCT03722108 2018-002374-46 Details | 2023-10-16 Interventional | 1/2 | 89 | Irinotecan Adenocarcinoma Adenocarcinoma … Adenocarcinoma … | Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate
efficacy and safety analysis - | |||
| NCT03330405 2017-001509-33 Details | 2023-10-13 Interventional | 1/2 | 223 | Antibodies, Mon… Avelumab Talazoparib Neoplasms Avelumab in Com… | The study was terminated since there was no need for further safety or efficacy data to be
collected. The participants having benefit from the investigational treatments have been moved
to a continuation study (NCT05059522). - | |||
| NCT01891981 Details | 2023-10-13 Interventional | 1 | 16 | Immunotoxin HA2… Leukemia Leukemia, Lymph… Precursor Cell … | Ph I Exempt as it did not proceed to the Phase II terminated early by the supporter - | |||
| NCT05813314 Details | 2023-10-12 Interventional | 1 | 36 | Natriuretic Pep… Achondroplasia | The BMN 111-104 study has terminated as further optimization of the approach to achieve bio
equivalence is required. The study termination was not due to any patient safety concerns. - | |||
| NCT04965818 Details | 2023-10-12 Interventional | 1 | 38 | Futibatinib Carcinoma, Non-… Advanced or Met… KRAS Gene Mutat… Non-Small Cell … | Strategic decision by sponsor. - | |||
| NCT04598321 Details | 2023-10-12 Interventional | 1 | 1 | Talazoparib Carcinoma, Ovar… Cystadenocarcin… Fallopian Tube … Ovarian Neoplas… BRCA1 Mutation BRCA2 Mutation Fallopian Tube … High Grade Sero… Ovarian Cancer | termination of research grant agreement - | |||
| NCT03287908 2017-001997-41 Details | 2023-10-12 Interventional | 1 | 174 | Dexamethasone Pomalidomide Multiple Myelom… Neoplasms, Plas… Relapsed/Refrac… | business decision, not safety reasons. - | |||
| NCT01460654 Details | 2023-10-12 Interventional | 2 | 44 | Alendronate Methyltestoster… Testosterone Testosterone 17… Testosterone en… Testosterone un… Bone Diseases, … Hypogonadism Osteoporosis Osteopenia | - - | |||
| NCT05073484 Details | 2023-10-11 Interventional | 1 | 13 | Antibodies Immunoglobulins Neoplasms Advanced Solid … | Based on the disclosed global research data on the same target drugs, the company has carefully
considered and decided to terminate the project to optimize the existing research pipeline. - | |||
| NCT04629651 Details | 2023-10-11 Interventional | 1/2 | 0 | Captopril Fibrosis Myeloproliferat… Neoplasms Primary Myelofi… Bone Marrow Fib… Myeloproliferat… | PI discretion - |